Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Guideline Recommendations for Immune Checkpoint Inhibitor–Associated Thyroiditis

Epidemiology

  • Immune checkpoint inhibitor (ICI) therapy induces thyroiditis in 6 %–20 % of treated patients. 1

Hyperthyroid (Thyrotoxic) Phase Management

  • Beta‑blocker preference: Non‑selective beta‑blockers with alpha‑blocking activity (e.g., propranolol) are recommended to control adrenergic symptoms. 1
  • Antithyroid drugs: Methimazole and propylthiouracil are ineffective for thyroiditis‑related thyrotoxicosis and should be avoided, except in thyroid‑storm emergencies. 1
  • Monitoring: Check serum TSH and free T4 every 2–3 weeks during the thyrotoxic phase to detect transition to hypothyroidism. 1
  • Typical duration with ICI: The thyrotoxic phase averages ≈ 1 month after ICI initiation; hypothyroidism usually follows ≈ 1 month later. 1
  • Conservative therapy: Symptom control with beta‑blockers is sufficient; routine use of antithyroid drugs is not indicated. 1

Hypothyroid Phase Management

  • Indication for levothyroxine: Initiate levothyroxine in any patient who becomes symptomatic (fatigue, weight gain, cold intolerance, constipation, depression) with any TSH elevation. 1
  • Timing of initiation: Start levothyroxine immediately when hypothyroidism is diagnosed in ICI‑related thyroiditis. 1
  • Corticosteroid use: High‑dose systemic corticosteroids are rarely required for thyroid dysfunction caused by ICIs. 1

Ongoing Monitoring in ICI‑Treated Patients

  • Perform thyroid function tests every 4–6 weeks initially, then each treatment cycle for the first 3 months, and thereafter every second cycle. 1

Long‑Term Outcomes

  • Permanent hypothyroidism typically develops ≈ 1 month after the thyrotoxic phase and ≈ 2 months after the start of ICI therapy. 1

Safety Considerations

  • In patients with suspected central hypothyroidism or hypophysitis, give physiologic‑dose steroids 1 week before starting thyroid hormone replacement to prevent adrenal crisis. 1

Referral to Endocrinology

  • Refer for:
    • Suspected or confirmed hypophysitis,
    • Complex primary hypothyroidism,
    • Persistent thyrotoxicosis > 6 weeks,
    • Need for additional testing (TSH‑receptor antibodies, TSI, radioactive iodine uptake).
  • Endocrinology consultation is recommended in these scenarios. 1

Thyroiditis Treatment Approach

Immediate Assessment and Symptom Management

  • The American College of Cardiology recommends beta-blockers as the first-line treatment for symptomatic relief of adrenergic symptoms during the initial hyperthyroid phase 2, 3
  • Propranolol 60-80 mg orally every 4-6 hours or atenolol are preferred agents for rate control and symptom management 3
  • Monitor thyroid function every 2-3 weeks during the thyrotoxic phase to detect transition to hypothyroidism 3
  • NSAIDs are first-line therapy for mild to moderate thyroid pain and tenderness 3
  • Systemic glucocorticoids are indicated for severe symptoms, high fever, or pain unresponsive to NSAIDs 3

Hypothyroid Phase Treatment

  • Start levothyroxine for symptomatic patients with any TSH elevation 2
  • Start levothyroxine for asymptomatic patients with TSH >10 mIU/L 2
  • For patients <70 years without cardiovascular disease, start levothyroxine at 1.6 mcg/kg/day based on ideal body weight 2
  • For patients >70 years or with cardiac disease, start levothyroxine at 25-50 mcg/day and titrate gradually 2

Special Clinical Scenarios

  • ICI therapy can be continued in most cases of thyroiditis, unlike other immune-related adverse events 4, 5
  • High-dose corticosteroids are rarely required for thyroid dysfunction 4, 5
  • Monitor thyroid function every 4-6 weeks initially 2

Thyroid Storm

  • Immediate treatment required: propranolol (or alternative beta-blocker), propylthiouracil or methimazole, potassium iodide, dexamethasone, and aggressive IV hydration (at least 2L normal saline initially) 3
  • Target heart rate <100 bpm with continuous cardiac monitoring 3

Monitoring and Follow-Up

  • Reduce or discontinue levothyroxine if TSH becomes suppressed, suggesting overtreatment or recovery of thyroid function 2
  • If thyrotoxic phase persists beyond 6 weeks, obtain endocrinology consultation 3
  • Endocrinology referral is also indicated for unusual presentations, difficulty titrating therapy, or concern for central hypothyroidism 2
  • In elderly or cardiac patients, avoid starting full replacement doses of levothyroxine due to risk of precipitating arrhythmias or angina 2